India to Begin Domestic Production of Clavulanic Acid, Key Antibiotic Ingredient, Under PLI Scheme

Dr. Arunish Chawla, Secretary of the Department of Pharmaceuticals, announced that India is set to begin production of Clavulanic Acid, a critical component in the antibiotic Augmentin, which treats various bacterial infections. Speaking to ANI, Dr. Chawla shared that the Production Linked Incentive (PLI) scheme for bulk drugs has attracted significant investment, enabling the local manufacture of both Penicillin G and Clavulanic Acid, which are essential for producing half of the beta-lactam antibiotics available in the market.

Dr. Chawla highlighted that India once produced these bulk drugs but lost ground to foreign competition. However, with the success of the PLI scheme, India is poised to regain its footing in antibiotic production. The new manufacturing plants are expected to be commissioned soon, marking a significant milestone in reducing reliance on imports and strengthening India’s pharmaceutical industry.